Figure 5. Metformin blocks growth of HR‐defective tumors in vivo.

• A, B
  ID8 Trp53‐deleted (A) and Trp53/Brca2‐deleted (B) ovarian tumor cells were injected in the ovary of C57/BL‐6 mice. After 1 month, animals were treated with vehicle or metformin (100 mg/kg) for 4 weeks. Results are the mean and SEM of 8 controls and 8 metformin‐treated animals (A) or of eight controls and 12 metformin‐treated animals (B). Statistical significance of two‐tailed unpaired Mann–Whitney U‐tests: *P = 0.0446.
• C
  Nude mice with orthotopically implanted BRCA1 WT OVA260 ovarian tumors were treated with vehicle or metformin (100 mg/kg) for 4 weeks. Results are the mean and SEM of five control tumors and five metformin‐treated tumors. Statistical significance of two‐tailed unpaired Mann–Whitney U‐test: P = 0.8016.
• D
  Mice with orthotopically implanted BRCA1‐mutated OVA265 ovarian tumors were treated with vehicle or metformin (100 mg/kg) for 4 weeks. Results are the mean and SEM of seven control tumors and seven metformin‐treated tumors. Statistical significance of two‐tailed unpaired Mann–Whitney U‐tests: *P = 0.0105.